The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma by Manier, Salomon et al.
The LIN28B/let-7 axis is a novel
therapeutic pathway in Multiple Myeloma
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Manier, S., J. T. Powers, A. Sacco, S. V. Glavey, D. Huynh, M. R.
Reagan, K. Z. Salem, et al. 2016. “The LIN28B/let-7 axis is a
novel therapeutic pathway in Multiple Myeloma.” Leukemia 31
(4): 853-860. doi:10.1038/leu.2016.296. http://dx.doi.org/10.1038/
leu.2016.296.
Published Version doi:10.1038/leu.2016.296
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630451
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple 
Myeloma
Salomon Manier1,2,3, John T. Powers4, Antonio Sacco1, Siobhan V. Glavey1, Daisy Huynh1, 
Michaela R. Reagan1, Karma Z. Salem1, Michele Moschetta1, Jiantao Shi1, Yuji Mishima1, 
Catherine Roche-Lestienne3, Xavier Leleu2, Aldo M. Roccaro1, George Q. Daley4, and Irene 
M. Ghobrial1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston 
02215 MA, USA
2Service des Maladies du Sang, CHRU Lille, 59000 Lille, France
3Jean-Pierre Aubert Research Centre, INSERM U1172, University Lille 2, 59000 Lille, France
4Division of Pediatric Hematology/Oncology, Children’s Hospital, Harvard Medical School, Boston 
02215 MA, USA
Abstract
MYC is a major oncogenic driver of Multiple Myeloma (MM) and yet almost no therapeutic 
agents exist that target MYC in MM. Here we report that the let-7 biogenesis inhibitor LIN28B 
correlates with MYC expression in MM and is associated with adverse outcome. We also 
demonstrate that the LIN28B/let-7 axis modulates the expression of MYC, itself a let-7 target. 
Further, perturbation of the axis regulates the proliferation of MM cells in vivo in a xenograft 
tumor model. RNA sequencing and gene set enrichment analyses of CRISPR-engineered cells 
further suggest that the LIN28/let-7 axis regulates MYC and cell cycle pathways in MM. We 
provide proof-of-principle for therapeutic regulation of MYC through let-7 with an LNA-GapmeR 
containing a let-7b mimic in vivo, demonstrating that high levels of let-7 expression repress tumor 
growth by regulating MYC expression. These findings reveal a novel mechanism of therapeutic 
targeting of MYC through the LIN28B/let-7 axis in MM that may impact other MYC dependent 
cancers as well.
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Introduction
Multiple myeloma (MM), a tumor originating from plasma cells in the bone marrow (BM), 
has an annual incidence of 6.3 new cases per 100,000 individuals1. Despite the major 
advances in therapy for MM, it remains incurable and there are no targeted therapies for 
MM, in part due to the lack of therapies that target specific oncogenes involved in the 
pathogenesis of the disease. Genomic events such as chromosomal translocations, copy 
number variation, somatic mutations, and epigenetic modifications all contribute to gene 
deregulation of specific oncogenes or tumor suppressors during MM tumorigenesis2. Among 
those, MYC plays a central role in the progression of the disease. Approximately two thirds 
of newly diagnosed patients harbor MYC activation, which correlates with adverse clinical 
outcome3. MYC activation is commonly driven by translocation or copy number gain of 
chromosome 8q24, which contains the MYC locus4, 5. Despite the dominant role of MYC in 
MM, there are very few therapeutic options targeting MYC. Previous studies have attempted 
to target MYC by using a bromodomain inhibitor to target BET proteins, which regulate 
MYC6, 7.
The let-7 miRNA was originally discovered in C. elegans as a regulator of developmental 
timing and cell proliferation8. Let-7 expression increases as cells become more 
differentiated. In humans, let-7 miRNAs comprise a family of 12 members distributed over 8 
genomic loci9 that are often repressed in cancer10. Let-7 miRNAs function as a tumor 
suppressor through regulation of key oncogenes, including MYC and RAS, by binding 
specific sites in the mRNA 3'-UTRs and inhibiting translation of these targets11,12. Low 
expression of let-7 family members is associated with poor prognosis in several cancer 
types13, 14.
In humans, let-7g and let-7i are located individually on chromosomes 3 and 12 respectively. 
The remaining let-7 family members are distributed among six miRNA clusters at 
genetically distinct loci. The let-7a2 and let-7c clusters are involved in hematopoietic stem 
and progenitor cell (HSPC) homeostasis by regulating the balance between TGFβ and Wnt 
signaling15, whereas the let-7e cluster is highly expressed in HSPC and confers 
hematopoietic phenotypes16. However, the exact role of the various let-7 family members in 
mammalian development has not yet been fully elucidated17,18, in large part because it is 
technically difficult to knock out multiple let-7 family members in the same individual cell. 
Moreover, these multiple let-7 family members are likely to have functionally similar roles.
LIN28B is an RNA-binding protein highly expressed in stem cells and developing tissues 
where it impairs the processing of let-7 precursors into mature, functional miRNAs19. Over-
expression of LIN28B has been reported in several cancers20 and is associated with 
advanced disease and poor outcome in ovarian14, breast21, colon22, hepatocellular 
carcinoma23, 24 and neuroblastoma25, 26. Transgenic LIN28B has been shown to induce 
multiple tumors types in mice including liver, Wilms, colon, and neuroblastoma, all of which 
solidify its oncogenic role24, 25,27,28. LIN28B has also been reported to act through a let-7-
independent manner, especially via regulation of IGF224.
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While the LIN28B/let-7 axis has been implicated in the regulation of MYC in different 
tumor types20, its potential as a therapeutic target has not yet been explored, specifically in 
blood cancers. In this study, we define the mechanistic activity of the LIN28/let-7 axis in 
clonal plasma cells and establish a potential therapeutic role of this pathway in targeting 
MYC in MM, which could lead to significant therapeutic advances in MM and other 
cancers.
Methods
Cell and primary cells
The MM cell lines MM.1S and RPMI8226 were purchased from ATCC; KMS12BM and 
MOLP-8 were purchased from DSMZ and KMM-1 was purchased from JCRB Cell Bank. 
The MM.1S GFP+Luc+ cell line was generated by retroviral transduction with the pGC-
GFP/Luc vector (gift of A. Kung, Dana-Farber Cancer Institute). Cells were authenticated by 
short tandem repeat DNA profiling. Primary samples were obtained from bone marrow 
aspiration from both MM patients and healthy controls. Plasma cells were isolated using 
CD138+ microbead selection (Miltenyi Biotec®, Auburn, CA). All patients were diagnosed 
with active MM at diagnosis or at relapse, based on criteria of the International Myeloma 
Working Group29. Informed consent was obtained from all patients and healthy volunteers 
in accordance with the Declaration of Helsinki protocol.
Lentivirus-mediated shRNA silencing
LIN28B shRNA in lentiviral plasmid (TRCN0000122191 and TRCN0000122599) and 
control shRNA (SHC216V) were purchased from Sigma-Aldrich. For viral production, 293T 
cells were transfected with lentiviral gag/pol, VSV-G, and the lentiviral plasmid, at a ratio of 
1:0.4:1, using Lipofectamine 2000. Viral particles were harvested after 24hrs and 48hrs. Two 
milliliters of viral supernatant were used to infect 1,000,000 cells in the presence of 
Polybrene (8 ng/µL). Infected cells were selected on Puromycin antibiotic before subsequent 
analysis.
Lentivirus-mediated CRISPR silencing
LentiCRISPRv2 (Addgene plasmid #52961) and lentiCRISPR:EGFPsgRNA-1 (#51760) 
were gifts from Feng Zhang30. LIN28B sgRNA were designed using the MIT Optimized 
CRISPR design tool. Sequences of sgRNA were: 5’-CATCGACTGGAATATCCAA G-3’ for 
sgLIN28B#1 and 5’-CAGAGCAAACTATTCATGGA-3’ for sgLIN28B#2. Human U6 
(hU6) primer 5’-GAGGGCCTATTTCCCATGATT-3' was used for validation by Sanger 
sequencing after cloning. Lentivirus production was processed as above for shRNA lentiviral 
production.
miRNA mimic transfection
Cell lines were transfected with hsa-let-7b mimic or with a control probe (mirVana miRNA 
mimic, Life Technology) at final concentration of 40 nM, using Lipofectamine 2000 
according to manufacturer’s instructions (Invitrogen). Culture medium was changed to 
regular medium 24 hours after transfection and cells were used for functional assays at 48 
hours. For the rescue experiment, MOLP-8 sgGFP or sgLIN28B#1 were transfected with a 
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control probe or a mix of anti-let-7a, b, d, and g (mirVana anti-miRNA, Life Technology) at 
a final concentration of 40 nM, using X-tremeGENE 9 according to manufacturer’s 
instructions (Roche, Life Science).
Quantitative reverse transcription PCR
Mature miRNA and mRNA expression were analyzed by qRT-PCR using SYBR green dye 
on an Applied Biosystems AB7500 Real Time PCR System. All PCR reactions were run in 
triplicate. Ct values were normalized on RNU6B and 18S, respectively, and relative changes 
were calculated using the 2-ΔΔCt. The following primer sequences were used: LIN28B-F: 
5’-GCCCCTTGGATATTCCAGTC-3’; LIN28B-R: 5’-TGACTCAAGGCCTTTGGAAG-3’; 
MYC-F: 5’-TCGGTCCTCGGATTCTCTGCTCT-3’; MYC-R: 5’-
GCCTCCAGCAGAAGGTGATCCA-3’; KRAS-F: 5’-
TGTGTCTCATATCAGGTTGACGA-3’; KRAS-R: 5’ -
CAAGAGTCGAGTGTGGTCTCA-3’; CCND1-F: 5’-
TCTACACCGACAACTCCATCCG-3’; CCND1-R: 5’-
TCTGGCATTTTGGAGAGGAAGTG-3’; DICER1-F: 5’-
CTCCTACCACTACAATACTATCACT-3’; DICER1-R: 5’-
GGTCTTCATAAAGGTGCTTGGT-3’; E2F6-F: 5’-GCGGAGAGTGTATGACATCACC-3’; 
E2F6-R: 5’-GTCAGAAAGTTCCTCCTGTAGCT-3’; HMGA1-F: 5’-
GAAGTGCCAACACCTAAGAGACC-3’; HMGA1-R: 5’-
GGTTTCCTTCCTGGAGTTGTGG-3’; pri-let-7d-F: 5’-
GCCAAGTAGAAGACCAGCAAG-3’; pri-let-7d-R: 5’-
CAAGGAAACAGGTTATCGGTG-3’; pri-let-7g-F: 5’-GTTCCTCCAGCGCTCCGTT-3’; 
pri-let-7g-R: 5’-CCATTACCTGGTTTCCCAGAGA-3’. Sequences for full mature let-7 
miRNA were used to design let-7 forward primers, in combination with universal 3’ miRNA 
reverse primer.
Immunoblotting
Whole-cell lysates were subjected to SDS-PAGE, and transferred to polyvinyldene fluoride 
(PVDF) membrane (Bio-Rad Laboratories). For immunoblotting we used antibodies against 
LIN28B (Cell signaling #4196S), c-MYC (Cell signaling #9402S) and GAPDH (Cell 
signaling #2118S).
Proliferation assay
Proliferation rates were measured by DNA synthesis, using [3H]-thymidine uptake (Perkin 
Elmer, Boston, MA) as described31.
RNA-sequencing
RNA was extracted using Qiagen RNeasy Kit. Whole RNA (500ng) was subject to library 
preparation with NEBNext Ultra RNA Library prep for Illumina kit (BioLabs). A single 
unique index was assigned to each sample. Quality control of the libraries was evaluated by 
Bioanalyzer analysis with High Sensitivity chips (Agilent). Libraries were quantified by 
qPCR (Kapa assay) and multiplex before sequencing on a HiSeq 2000 (2×50bp paired-end 
reads) at the Biopolymers Facility of Harvard Medical School. Cutadapt was used to trim 
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adapters; trimmed reads were aligned to Human reference genome (GRCh37) with tophat2; 
and read counts for each gene was calculated by HT-seq. RNA-seq data have been deposited 
to the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession 
numbers GSE71100.
In vivo studies
SCID/bg mice (n=5/group) used for xenograft experiments were injected subcutaneously 
with MOLP-8 cells that were infected with either a LIN28B shRNA, or a control shRNA. 
Tumor volume (measured by caliper) were calculated by the formula: length × width2 × 
0.5232. To evaluate the effect of let-7 LNA-GapmeR (containing the sequence 5’-
AGGTAGTAGGTTGTGT-3’), SCID/bg mice (n=5/group) were i.v. injected with 5×106 
MM.1S GFP+Luc+ cells on day 0; followed by i.p. injections of let-7 (20 mg/kg) or control 
LNA-GapmeR 2 times a week starting on day 2. Tumor growth was evaluated by 
bioluminescence imaging (BLI) and mice were followed for survival.
Results
Deregulation of LIN28B/Let-7 axis in MM
We first sought to determine whether LIN28B is deregulated in MM, and therefore analyzed 
two independent publicly available gene expression profiling datasets containing plasma 
cells from patients with newly diagnosed MM and healthy control donors. These included 
GSE24080 and GSE2658, containing 22 normal donor plasma cell samples and 559 plasma 
cell samples from patients with newly diagnosed patients - both from UAMS - and 
GSE16558, with 5 normal donor plasma cells and 65 plasma cell samples from patients with 
newly diagnosed MM. We identified a significant overexpression of LIN28B in MM cells 
compared to normal plasma cells in both datasets (Fig. 1a). We next sought to determine the 
prognostic relevance of LIN28B in the survival of patients with MM. We performed Kaplan 
Meier analysis on a cohort of 542 patients treated with Total Therapy 2 (GSE2658), and 
observed that high expression of LIN28B was associated with significantly worse overall 
survival, (p=0.0075) (Fig. 1b).
Therefore, we explored whether targeting the LIN28B/let-7 axis would have a 
therapeutically relevant role in MM and silenced LIN28B using two lentiviral short hairpins 
(shRNA) constructs that target the mRNA coding sequence in several LIN28B-expressing 
MM cell lines: MOLP-8, KMS12BM, RPMI8226 and KMM-1. The shRNAs caused 
degradation of LIN28B mRNA in all cell lines (Fig. 1c). Moreover, pri-let-7 RNA was not 
modified as shown for pri-let-7g, consistent with the post-transcriptional regulation of let-7 
by LIN28B (Supplemental Fig. 1a).
LIN28B regulates let-7 and MYC in MM
Consistent with the role of LIN28B in regulating let-7 expression, we observed de-
repression of let-7 family members in cells with LIN28B knockdown compared to non-
targeting control (Fig. 2a). We next analyzed the downstream targets of LIN28B/let-7 and 
found a decreased protein expression of MYC in LIN28B-silenced cells in several MM cell 
lines (Fig. 2b). Moreover, knockdown of LIN28B significantly impaired the proliferation of 
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these cell lines tested (Fig. 2c). Consistent with these observations, we identified, through 
gene set enrichment analysis (GSEA), an enrichment of let-7 target genes in MM patient 
samples who displayed a high level of LIN28B expression in two independent datasets 
(GSE2658 and MMRC dataset), suggesting that LIN28B represses let-7 and indirectly 
enriches let-7 target expression (Fig. 3a).
In addition, among let-7 target genes, MYC expression significantly correlated with LIN28B 
expression level in two independent datasets (GSE16558 and GSE2658). As shown in 
Supplemental Fig. 1b, a strong correlation existed between LIN28B and MYC in MM tumor 
cells from patient samples in GSE16558 and in total therapy 2 GSE2658, p<0.028 and 
p<0.001, respectively.
To validate whether MM cells are dependent on LIN28B for growth, we examined tumor 
growth of MOLP-8 cell line with a LIN28B specific hairpin or non-targeting control in a 
xenograft mouse model using SCID/bg mice. Tumor growth was significantly lower in mice 
injected subcutaneously with LIN28B knockdown compared to scrambled control (Fig. 3b), 
resulting in a significant prolongation of survival in the experimental group, p = 0.0045 (Fig. 
3c). In addition, MYC expression was significantly reduced in cells obtained ex-vivo from 
mice injected with LIN28B knockdown compared to scrambled control (Supplemental Fig. 
1c).
Together, these data suggest a deregulation of LIN28B/let-7 axis in a proportion of patients 
with MM and can function as a novel therapeutic target of MYC regulation in MM.
MYC and cell cycle pathways are highly enriched in cells with high expression of LIN28B
To control for possible off-target effect of shRNAs and for incomplete LIN28B knockdown 
mitigating the observed phenotype, we next used CRISPR/Cas9 technology to knock-out 
(KO) LIN28B in the MOLP-8 cell line. Single guide RNAs (sgRNA) targeting exons 2 and 3 
of LIN28B were used (Supplemental Fig. 2a). Significant decrease in LIN28B protein levels 
were observed, indicating high frequency LIN28B KO in the cell population. MYC protein 
level were similarly decreased (Fig. 4a). Moreover, LIN28B KO resulted in de-repression of 
let-7, which was consistent with the shRNA experiment (Fig. 4b). Moreover, LIN28B KO 
led to the reduced proliferation by thymidine uptake assay (Fig. 4c).
For further characterization of the LIN28B/let-7 axis in MM, we performed RNA-
sequencing of the LIN28B CRISPR-KO cells and GFP sgRNA control cells in triplicate. 
LIN28B was confirmed to be the most significantly down-regulated gene in LIN28B-
silenced cells (Fig. 5a), confirming efficient knock-out. We then queried the top 150 down 
regulated genes in LIN28B KO cells against the MSigDB ‘H’ hallmark, ‘c2’ canonical 
pathways and ‘c3’ transcription factor target gene sets. The 10 most enriched gene sets were 
present in E2F cell cycle pathway regulation (Fig. 5b). Of note, E2F2, a let-7 target gene, 
was one of the most down-regulated genes in LIN28B KO cells. Moreover, we found a 
significant enrichment of let-7 target genes in control compared to LIN28B KO cells (Fig. 
6a). Using an unsupervised GSEA analysis of the whole data set against the MSigDB ‘H’ 
hallmark gene sets, we found that MYC pathway gene set was in the top 5 genes sets, which 
further suggests that the LIN28B/let-7 axis regulates MYC in MM. Moreover, significant 
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enrichment of MYC pathway in control cells was also validated using several MYC pathway 
gene sets (Fig. 6b). These results support a model where LIN28B represses let-7, thereby 
enriching let-7 targets such as E2F2 and MYC in MM.
Given that LIN28B has been reported to act both in a let-7-dependent and independent 
manner33, we next asked whether the functional role of LIN28B is mediated via let-7 in 
MM. We thus performed a rescue experiment by transfection of a let-7 inhibitor into 
LIN28B-KO MOLP-8 cells. We observed a significant decrease of let-7 family members in 
LIN28B KO cells plus the anti-let-7 (Fig. 6c). Let-7 inhibition also significantly rescued cell 
proliferation (Supplemental Fig. 2b), indicating that let-7 is likely the main target of direct 
regulation by LIN28B, in let-7 dependent manner in MM.
Deregulation of let-7 in MM
Given that we demonstrated that LIN28B regulates MM proliferation through let-7, we 
sought to define the direct role of let-7 in MM. We first assessed the expression level of let-7 
family members in primary bone marrow MM CD138+ cells compared to healthy control 
CD138+ bone marrow plasma cells by qRT-PCR. Let-7 miRNAs were lower in plasma cells 
from six patients with relapsed MM and in four MM cell lines, as compared to plasma cells 
from three healthy donors (Fig. 7a). To determine whether let-7 directly regulates MYC in 
MM, we transfected a let-7b mimic into MM.1S cells (Supplemental Fig. 3a) and observed a 
reduction of cell proliferation (Fig. 7b) as well as a decrease level of MYC protein 
(Supplemental Fig. 3b). To validate these findings in patient samples, we assessed the 
correlation between let-7 and MYC expressions in publicly available gene expression 
profiling with matched miRNA array from MM patients (GSE16558). We found a 
significant inverse correlation between expression of let-7b and g and the expression level of 
MYC in a cohort of 60 patients (Fig. 7c). These data support the idea that LIN28B acts in a 
let-7-dependent manner in MM and suggest that low expression levels of let-7 in MM 
patients contributes to MYC dysregulation and tumor proliferation.
Let-7 as a potential therapeutic target that regulates MYC in MM
We next sought to confirm the importance of let-7 in MM in vivo and to assess whether let-7 
could serve as a therapeutic strategy to directly target MYC in MM. We therefore developed 
a let-7 Locked Nucleic Acid (LNA)-GapmeR mimic, which was designed based on the seed 
region of let-7 miRNAs to efficiently mark let-7 target genes for degradation by RNAse H. 
We first tested the ability of the let-7 LNA-GapmeR to decrease let-7 target genes in vitro. 
MM.1S cell line was cultured in presence of a control probe or three different concentrations 
of let-7 LNA GapmeR (10nM, 100nM and 1uM). By qRT-PCR we observed a consistent 
decrease of MYC, KRAS, CCND1, E2F6, DICER1 and HMGA1 expression levels in 
parallel to increased concentration of the GapmeR (Supplemental Fig. 4a). We next tested 
the let-7 LNA-GapmeR in vivo in a xenograft mouse model. SCID/bg mice were injected 
with 5×106 MM.1S GFP+Luc+cells intravenously, followed by intraperitoneal (i.p.) 
injections of let-7 LNA-GapmeR two times a week. The treatment was well tolerated and 
did not induce obvious toxicity or weight loss. The tumor growth was evaluated by BLI, and 
was significantly reduced in the group of mice that received let-7 LNA-GapmeR as 
compared to the control group, p=0.018 (Fig. 8a and Supplemental Fig. 4b). This was 
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associated with consequent significant survival benefit, p=0.026 (Fig. 8b). Ex-vivo, MM 
cells were analyzed for MYC expression, confirming the repression of MYC in the let-7 
LNA-GapmeR group (Fig. 8c). This experiment provides proof of principle that let-7 could 
represent a new therapeutic approach targeting MYC in MM.
Discussion
In this study, we describe the role of the LIN28B/let-7 axis in MM and identify let-7 as a 
potential new therapeutic approach for targeting MYC. High expression of LIN28B in MM 
is associated with both adverse outcomes and MYC overexpression. LIN28B represses let-7 
expression in MM cells, resulting in deregulation of MYC protein and cell proliferation in 
vitro and in vivo. A pathway enrichment analysis in LIN28B KO cells reveals the 
importance of the MYC and E2F cell cycle pathways within the LIN28B/let-7 axis. 
Moreover, LIN28B-induced proliferation and MYC deregulation is let-7 dependent. The 
tumor growth impairment in vivo by administration of a let-7b based LNA-GapmeR 
provides proof of principle for a new therapeutic option to target MYC in MM 
(Supplemental Fig. 5).
Let-7 miRNAs have been described as tumor suppressor in several cancers, by targeting 
major oncogenic pathways9. Copy number loss34–36 or epigenetic silencing37 of individual 
let-7 family members has been reported in some cancers. In MM, several let-7 genes are 
located in frequently deleted regions, such as let-7g at 3p21, let-7i at 12q14, or let-7a-2 at 
11q24. These copy number aberrations might participate in deregulation of the LIN28B/let-7 
axis in MM. Here, we have described a mechanism of regulation of let-7 miRNAs in MM 
involving LIN28B, which inhibits let-7 miRNAs, resulting in deregulation of the MYC and 
E2F cell cycle pathways. Although LIN28B has been reported in liver cancer to act through 
both let-7-dependent and let-7-independent manners24, our findings suggest the 
predominance of a let-7-dependent mechanism in MM.
LIN28B is located in the 6q21 cytogenetic band, which is amplified in some cases of 
neuroblastoma, resulting in LIN28B overexpression25. In MM, previously published CGH 
array did not find amplification at 6q21 locus38. The increased expression of LIN28B might 
therefore result from epigenetic changes such as altered methylation or histone modification 
or deregulation of upstream processes. MiR-125b was reported to inhibit LIN28B in 
embryonic stem cells as well as in some case of cancers25, 39, 40. Interestingly, miR-125b is 
located in 11q23, which is frequently deleted in MM. Of note, let-7 miRNAs themselves 
have also been reported to regulate LIN28B expression, in a feedback loop manner41. 
Moreover, a recent report suggests that inactivation of DIS3 increases LIN28B expression in 
MM42, by impairing its mRNA degradation. DIS3 is an exosome endoribonuclease involved 
in the turnover and degradation of mRNA in the cytoplasm. Strikingly, DIS3 is one of the 
most frequently mutated genes in MM43, 44, further suggesting a central role for LIN28B/
let-7 axis in MM.
Despite key roles for MYC in MM, there are very few therapeutic options targeting MYC. 
Previous studies attempted to target MYC by using a bromodomain inhibitor to target BET 
proteins, which regulate MYC6, 7. The clinical impact of these inhibitors is being elucidated 
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in early phase clinical trials with some potentially promising results in hematological 
malignancies. Our findings provide proof of principle that therapeutic use of let-7 can allow 
the repression of multiple oncogenes concurrently in MM. We show that in vivo use of let-7 
effectively regulates MYC, which is an essential regulator of tumor progression in MM and 
other cancers. Our findings indicate the importance of let-7 regulation in MM and suggest 
that let-7 may be an effective therapeutic option that can directly target MYC in MM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. LIN28B expression level in MM
LIN28B expression level in MM patients, compared to healthy individuals, by analysis of 
(a) Left panel: GSE16558 (5 normal donor plasma cells and 65 plasma cell samples from 
patients with newly diagnosed MM) and right panel: GSE24080 – containing 22 normal 
donor plasma cell samples - and GSE2658 – 559 plasma cell samples from patients with 
newly diagnosed patients - both from UAMS, which were normalized using GeneSpring. (b) 
Kaplan-Meier analysis of 542 patients with MM of the Total Therapy 2 cohort (GSE2658). 
Patients were classified as high vs. low expression of LIN28B based on the mean expression 
level. LIN28B was associated with significantly worse overall survival, (p=0.0075). (c) 
MOLP-8, KMS12BM, RPMI 8226 and KMM-1 cells infected with control shRNA, or 2 
different LIN28B shRNAs, were studied for relative expression of LIN28B mRNA as 
determined by qRT-PCR.
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Figure 2. The LIN28B/let-7/MYC axis in Multiple Myeloma
(a) relative expression of mature let-7 miRNA species as determined by quantitative PCR in 
4 MM cell lines infected with control shRNA or 2 different LIN28B shRNAs. (b) Protein 
blot analysis for LIN28B and MYC expression in MOLP-8, KMS12BM, RPMI 8226 and 
KMM-1 cells infected with control shRNA or 2 different LIN28B shRNAs, and (c) 
proliferation assay by thymidine uptake over a 48hr time in the same cell lines. P values 
were obtained by two-tailed Student t test (*P < 0.05)
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Figure 3. The LIN28B/let-7 axis in data sets and in vivo
(a) GSEA analysis showing an enrichment of let-7 target genes in MM patients who display 
a high level of LIN28B expression in two independent datasets (GSE2658 and MMRC 
dataset). (b) Tumor volume and (c) survival of SCID/bg mice (5 per group) injected 
subcutaneously with 5.106 MOLP-8 cells expressing pLKO control shRNA or 
pLKO.LIN28BshRNA; average survival time was 26 days versus 33 days, respectively, P = 
0.0045. Bars indicate mean ± SD (n = 3).
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Figure 4. LIN28B KO with CRISPR/Cas9 leads to MYC regulation and Let-7 upregulation
MOLP-8 cell line was infected with a lentiCRISPR control (sgGFP) or 2 different 
sgLIN28B and studied for (a) Protein blot analysis, (b) relative expression of let-7 miRNAs 
by qRT-PCR and (c) proliferation assay by thymidine uptake. Bars indicate mean ± SD (n = 
3). P values were obtained by two-tailed Student t test (*P < 0.01).
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Figure 5. RNA sequencing and differential expression of genes downstream of LIN28B
RNA sequencing was performed with MOLP-8 lentiCRISPR control and sgLIN28B#2. (a) 
Scatter plot showing differential expression of genes ranked by Z score (metric of fold 
change and −log10 of the p value) of control cells against LIN28B-silenced cells. (b) Heat 
map of the top 150 down-regulated and up-regulated genes in LIN28B-silenced cells. Bar 
plot representing the p value of the top 10 gene sets enriched in the high-LIN28B signature.
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Figure 6. RNA sequencing and gene set enrichment analysis
(a) Gene set enrichment analysis (GSEA) for the let-7 target gene set and (b) GSEA analysis 
for several MYC gene sets in control vs. LIN28B KO cells. (c) MOLP-8 cells were infected 
with either lentiCRISPR control (sgGFP) or sgLIN28B#1, and transfected with a control 
probe or a mix of anti-let-7 b and g. Cells were studied for let-7 expression level by qRT-
PCR.
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Figure 7. Let-7 is down-regulated in MM and regulates MYC
(a) qRT-PCR analysis of let-7 family members in primary plasma cells from healthy donors 
and MM patients, as well as in 4 MM cell lines. (b) proliferation assay using thymidine 
uptake and 72 hours after transfection of a let-7b mimic or a control probe in MM.1S cells. 
Bars indicate mean ± SD (n = 3). P values were obtained by two-tailed Student t test (*P < 
0.05). (c) Correlation between let-7 and MYC expression in patients with MM. Scatter plot 
showing the correlation between let-7b and g, respectively, and MYC from GSE16558. A 
Pearson correlation coefficient and a two-tailed p value were computed for each of them.
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Figure 8. Increased expression of let-7 in vivo decreases MM proliferation
(a) Mice were followed by bioluminescence intensity (BLI), after injection of 5 million of 
MM.1S GFP+Luc+cells. SCID/bg mice (5 per group) were injected i.p. 2 times a week with 
20mg/kg of LNA control or LNA let-7 mimic. (b) Survival of the mice by Kaplan Meier 
analysis. Average survival time was 35 days in control group versus 42 days in LNA let-7 
mimic group, P = 0.0026. (c) qRT-PCR analysis of MYC in MM.1S cells ex vivo. Bars 
indicate mean ± SD (n = 3). P values were obtained by two-tailed Student t test (*P < 0.05).
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